LONDON (AP) — The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing ...

The task force determines which preventive services insurers must cover at no cost to patients.

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

(Reuters) -Health Secretary Robert F. Kennedy Jr. is planning to remove all the members of an advisory panel that determines ...

The drug is administered subcutaneously twice a year, making it easier for high-risk patients to comply with prophylaxis.

In 2024, studies suggested that lenacapavir, already used to treat people with HIV, was nearly 100% effective in stopping ...

The Trump administration is considering a dramatic cutback and eventual phasing out of the President’s Emergency Plan for ...

A federal judge on Thursday extended a temporary legal block that prevents Idaho from verifying the immigration status of ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...

Fourth District Judge Amanda Brailsford in Boise on Thursday also granted provisional class-action status to a lawsuit ...

Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...

HIV funding cuts. 820 words. 2 photos available. PHOENIX – Ending the spread of HIV in Arizona may become more difficult if ...